[USAGE OF PRONORAN® FOR TREATMENT OF ELDERLY PATIENTS WITH MILD COGNITIVE IMPAIRMENT].

Evaluated the effectiveness of Pronoran® for treatment of elderly patients with syndrome of mild cognitive impairment (MCI) with underlying dyscirculatory encephalopathy. The study involved 48 people: I (main) group--27 patients who in addition to basic therapy received Pronoran®, II (control) group--21 patients, received only basic therapy. We found that exposure to a 3-month treatment course for patients of the I (main) group showed significant improvement in terms of indicators characterizing orientation in space, short-term memory, counting ability, concentration, psychomotor pace, ability to learn.

[Special features of mild cognitive impairment in patients with metabolic syndrome].

Aim: to establish special features of mild cognitive impairment (MCI) in patients with chronic insufficiency of cerebral circulation (CICC) with metabolic syndrome (MS) depending on the age of patients. Investigation involved 282 patients aged 45-89 with CICC. All the patients also were divided into three groups depending on age; each group was divided into two subgroups: with MS and without it.

[Cognitive impairment in patients of different age with metabolic syndrome].

To analyze the characteristics of cognitive impairment (CI) in patients of different age with dyscirculatory encephalopathy (DE) and metabolic syndrome (MS). There were 503 patients aged 45-89 years with DE enrolled into the study, who were divided into two groups: patients without MS (n = 198) and with MS (n = 305). All patients were divided into three subgroups depending on age.

[ApoE gene polymorphism as a predictor of therapeutic response to treatment acetylcholinesterase inhibitor for elderly patients with Alzheimer's and vascular dementia types].

Unlabelled: Effectiveness of donepezil hydrochloride treatment for elderly patients with Alzheimer's and vascular dementia types depending on the ApoE genotype.

The Aim: To study the effectiveness of donepezil hydrochloride (Almer "Actavis") for elderly patients with Alzheimer's and vascular dementia types depending on the ApoE genotype.

Methods And Subjects: The 3-month clinical study included 38 elderly patients (mean age- (71.

[Use of memantine for elderly patients in the mild stage of Alzheimer's and vascular dementia].

To evaluate the efficiency menantine (antagonist of NMDA-type glutamate receptor) for treatment of the mild stage of Alzheimer and vascular dementia, we conducted a comprehensive neurological, experimental psychological, neurophysiological examination of 33 patients. It was found that the treatment course with memantine, 5-10 mg daily during 3 months resulted in reducing the severity of cognitive impairment, improved bioelectric activity of the brain in patients with dementia, and also helped to improve the patients' behavior, which resulted in stress loads on the surrounding people. It is shown that the treatment was well tolerated, and memantine may be recommended as one of the drugs for treatment of cognitive impairment accompanying aging in the mild stage of dementia of different genesis.